💡 *Could Medicare’s latest drug negotiations change the landscape of prescription costs?*
The Centers for Medicare and Medicaid Services has announced its second round of negotiations for crucial medications like Ozempic and Ibrance. This strategic move aims to lower prescription drug prices, potentially benefiting millions of beneficiaries while reshaping health policy under the Biden administration.
Unlock insights into how these negotiations could impact healthcare affordability and access—click to read more!
#SyenzaNews #HealthcarePolicy #CostEffectiveness